I can also now finally start to think about the other compounds RVX could develop......if Apabetalone hits on all its endpoints for MACE, CKD and Cognition....if that happens I don't think anyone doubts their ability to raise substantial funds.  Then instead of all their eggs in one basket, they could start developing multiple compounds in their pipeline...and who knows, maybe there's another Apabetalone in there, or maybe more than one.  

If Resverlogix develops a robust pipeline who knows....maybe we could see this little Calgary biotech become like a Biogen with a market cap in their range.